EODData

MEMBERSHIP REGISTER LOG IN

FRA, 0L8: Lantheus Holdings, Inc.

25 Aug 2025
LAST:

49.29

CHANGE:
 0.81		OPEN:
49.29		HIGH:
49.29		ASK:
0.00		VOLUME:
0
CHG(%):
1.62		PREV:
50.10		LOW:
49.29		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
25 Aug 2549.2949.2949.2949.290
22 Aug 2550.5650.5650.1050.1025
21 Aug 2547.8050.0047.8050.00200
20 Aug 2546.7746.7746.7746.77149
19 Aug 2547.4847.4847.4247.48149
18 Aug 2545.8545.8545.8545.85133
15 Aug 2546.2546.2546.1046.10133
14 Aug 2545.4845.4845.4845.48130
13 Aug 2545.7345.7344.5544.55130
12 Aug 2547.3747.3747.3647.36307

COMPANY PROFILE

Name:Lantheus Holdings, Inc.
About:Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Sector:Healthcare
Address:201 Burlington Road, Bedford, MA, United States, 01730
Website:https://www.lantheus.com
ISIN:US5165441032
LEI:5299005HUB5IOJGO7S39

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:15.46
PtB:3.39
PtS:2.27
EBITDA:494M
Shares:67.99M
Market Cap:3.351B

TECHNICALS

MA5:48.73
MA10:47.30
MA20:51.48
MA50:60.53
MA100:68.91
MA200:77.80
STO9:78.87
STO14:27.25
RSI14:32.08
WPR14:-14.59
MTM14:4.60
ROC14:0.10
ATR:2.70
Week High:50.56
Week Low:45.85
Month High:62.99
Month Low:41.72
Year High:107.38
Year Low:41.72
Volatility:82.87